Highlights Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
0.9131 ^USD	+1.68%		+1.47%	-3.88%

Dec. 19	IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	CI
Dec. 10	Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	CI

Highlights

IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	Dec. 19	CI
Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	Dec. 10	CI
Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer	Nov. 25	CI
IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001	Nov. 07	CI
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting	24-10-30	CI
Imunon Files for Stock Resale by Security Holders	24-08-29	MT
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-14	CI
Sector Update: Health Care Stocks Softer in Late Afternoon Trading	24-07-31	MT
Sector Update: Health Care	24-07-31	MT
Top Midday Decliners	24-07-31	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	24-07-30	MT
Sector Update: Health Care	24-07-30	MT
Top Midday Gainers	24-07-30	MT
Imunon Shares More Than Double on Ovarian Cancer Study Results	24-07-30	DJ
Imunon Says Phase 2 Trial Data of Ovarian Cancer Treatment Showed Increase in Overall Survival; Shares Jump	24-07-30	MT
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001	24-07-30	CI
Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer	24-06-24	CI
IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial	24-06-05	CI
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study	24-05-13	CI
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-13	CI
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	24-04-18	DJ
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	24-04-18	CI
Top Midday Gainers	24-03-28	MT
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	24-03-28	CI

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Highlights

Filters